Pfizer Inc. Files 8-K: Board and Executive Compensation Updates
Ticker: PFE · Form: 8-K · Filed: Oct 15, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: PFE
TL;DR
Pfizer's 8-K: New directors elected, exec pay changes. Stay tuned.
AI Summary
On October 10, 2024, Pfizer Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes information on the election of new directors and updates to compensatory arrangements for certain officers. Specific details regarding the financial impact or new appointments are not elaborated in this summary section of the filing.
Why It Matters
This filing signals potential shifts in corporate governance and executive incentives at Pfizer, which could influence strategic decisions and shareholder value.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance updates and executive compensation, which typically carry a low immediate risk to the company's operations.
Key Numbers
- 1-3619 — Commission File Number (Identifies Pfizer's filing with the SEC.)
- 13-5315170 — I.R.S. Employer Identification No. (Pfizer's tax identification number.)
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- October 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 66 Hudson Boulevard East (address) — Principal executive offices
- New York, New York (location) — City and State of principal executive offices
FAQ
What specific changes were made to Pfizer's board of directors?
The filing indicates the election of directors but does not specify the names of newly elected directors or any departures in this section.
Are there any details on the new compensatory arrangements for officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in this summary.
What is the significance of the 'Departure of Directors or Certain Officers' item?
This item signifies that there have been changes related to the company's directors or key officers, which could include resignations, terminations, or other departures.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 10, 2024.
What is Pfizer's state of incorporation and fiscal year end?
Pfizer Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-10-15 07:18:26
Filing Documents
- pfe-20241010.htm (8-K) — 33KB
- ex99_pressreleasex1024v2.htm (EX-99.1) — 11KB
- logo1a.jpg (GRAPHIC) — 5KB
- 0000078003-24-000185.txt ( ) — 214KB
- pfe-20241010.xsd (EX-101.SCH) — 3KB
- pfe-20241010_def.xml (EX-101.DEF) — 15KB
- pfe-20241010_lab.xml (EX-101.LAB) — 27KB
- pfe-20241010_pre.xml (EX-101.PRE) — 16KB
- pfe-20241010_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description Exhibit 99.1 Press Release of Pfizer Inc. dated October 15, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. Dated: October 15, 2024 By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel